In the 1980s, Soviet neuroscientists were racing to develop compounds that could protect the brains of cosmonauts and military pilots under extreme stress. One of the most promising results of that program was Semax — a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH) that demonstrated remarkable nootropic and neuroprotective properties without the hormonal side effects of its parent compound. Decades later, Semax remains one of the most fascinating — and clinically studied — research peptides in the cognitive enhancement space. Here is what the current science says.
What Is Semax?
Semax is a synthetic analogue of the ACTH(4–7) fragment — specifically the sequence Met-Glu-His-Phe-Pro-Gly-Pro. To improve stability, the natural sequence was modified with a Pro-Gly-Pro C-terminal extension, preventing rapid enzymatic degradation that would otherwise limit its bioavailability. The result is a peptide with a significantly extended half-life compared to native ACTH fragments, capable of producing meaningful CNS effects following intranasal or subcutaneous administration.
What makes Semax unusual among nootropic compounds is its primary mechanism: rather than acting as a neurotransmitter agonist or reuptake inhibitor, it functions upstream — stimulating the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). These neurotrophins govern neuronal survival, synaptic plasticity, and the formation of new neural connections. Semax essentially tells the brain to grow and protect itself, rather than simply altering the existing chemical environment.
Research Overview
Semax has been approved as a pharmaceutical in Russia since 1995, where it is marketed under the brand name Semax and prescribed for conditions including stroke rehabilitation, traumatic brain injury, optic nerve atrophy, and cognitive decline. This pharmaceutical history has generated a body of human clinical data that is rare for a nootropic peptide.
Key published research includes:
- Miasoedov et al. (1999) — One of the earliest clinical evaluations demonstrating Semax’s ability to improve attention, memory, and cognitive performance in healthy volunteers and patients with ischemic stroke. (PubMed: 10573097)
- Dolotov et al. (2006) — Rodent study demonstrating Semax increases BDNF and NGF mRNA expression in the hippocampus, providing a mechanistic basis for its neuroprotective and cognitive effects. (PubMed: 16696855)
- Shadrina et al. (2010) — Research showing Semax modulates gene expression related to neuroprotection and cognitive function after ischemic brain damage. (PubMed: 20145933)
- Kolomin et al. (2013) — Examined Semax’s role in regulating expression of genes related to neurotrophic factor signalling pathways, offering insights into long-term neuroplasticity. (Google Scholar)
Community Discussion
The nootropics research community has discussed Semax extensively on r/nootropics and r/Peptides. The most consistent themes include dramatically improved mental clarity within 30–60 minutes of intranasal administration, reduced anxiety without sedation — frequently described as an “alert calm” — enhanced motivation and working memory, and meaningful mood improvements, particularly in individuals with stress-related cognitive fatigue.
Potential Benefits Studied
- BDNF and NGF upregulation: Semax stimulates expression of key neurotrophins governing neuroplasticity, memory consolidation, and neuronal survival — a mechanism distinct from most nootropic compounds.
- Cognitive enhancement: Multiple studies and decades of clinical use in Russia support improvements in attention, working memory, information processing speed, and executive function.
- Neuroprotection and stroke recovery: Russian clinical protocols use Semax as a first-line intervention in acute ischemic stroke, with evidence of reduced infarct size and improved neurological outcomes.
- Anxiolytic effects: Semax appears to modulate dopaminergic and serotonergic signalling in ways that reduce anxiety without the sedation or dependency risk of conventional anxiolytics.
- Mood and motivation: Community and clinical reports suggest improvements in drive, motivation, and overall mood, likely mediated by dopaminergic tone and NGF upregulation.
- Optic nerve regeneration: A clinically documented application in Russian medicine — Semax has shown measurable improvements in visual acuity in optic nerve atrophy patients.
Dosage & Administration
Semax is most commonly administered intranasally, allowing direct CNS delivery via the olfactory pathway — bypassing the blood-brain barrier more efficiently than subcutaneous injection. Research dosing typically ranges from 300–900mcg per day intranasally, divided into one or two applications. Reconstitution in sterile saline solution and administration via nasal spray bottle is the standard approach, with 0.1% concentration solutions most commonly used. Effects are typically felt within 20–60 minutes and reported to last 6–12 hours. Subcutaneous injection is also used at similar dose ranges.
Where to Find Semax
Researchers can find high-purity Semax in the 5mg format at combatresearch.is. A pre-formulated nasal spray version is also available for researchers preferring a ready-to-use intranasal format.
Conclusion
Semax is one of the most scientifically credible nootropic peptides available to researchers today. Born from Soviet neuroscience programs and refined over decades of pharmaceutical use in Russia, its mechanism — upstream neurotrophin stimulation — places it in a category of its own. The combination of BDNF upregulation, established neuroprotective effects, and consistent reports of cognitive enhancement makes Semax one of the highest signal-to-noise compounds in the cognitive research space.
Disclaimer
This article is for informational and educational purposes only. Semax is a research peptide not approved by the FDA for human use in the United States. This content does not constitute medical advice. Always consult a qualified healthcare professional before using any research peptide or compound. Combat Research products are intended for licensed researchers and laboratory use only.
